The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders

Michael L. Sulkowski, Daniel A. Geller, Adam B. Lewin, Tanya K. Murphy, Andrew Mittelman, Ashley Brown, Eric A. Storch

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are needed to adequately treat non- and partial-responders. Emerging research suggests that interventions that augment learning and memory processes associated with exposure therapy (i.e., extinction training) may display promise in enhancing treatment response in OCRDs. As the most studied example, d-cycloserine (DCS) is a relatively safe cognitive enhancer that appears to accelerate treatment gains associated with exposure therapy. This article reviews research on the use of DCS and other putative cognitive modifiers as they relate to the treatment (or prospective treatment) of obsessive-compulsive disorder and other OCRDs.

Original languageEnglish (US)
Pages (from-to)317-324
Number of pages8
JournalCurrent Psychiatry Reviews
Volume10
Issue number4
DOIs
StatePublished - Jan 1 2014

Keywords

  • Brain-derived neurotrophic factor
  • Cognitive enhancer
  • D-cycloserine
  • Glucocorticoids
  • Memory reconsolidation
  • Obsessive-compulsive disorder
  • Yohimbine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders'. Together they form a unique fingerprint.

  • Cite this